Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Combination of three technologies makes potential treatment effective against aggressive brain tumor

Combination of three technologies makes potential treatment effective against aggressive brain tumor

Black, Hispanic patients with advanced liver cancer have lower chance of receiving immunotherapy

Black, Hispanic patients with advanced liver cancer have lower chance of receiving immunotherapy

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

Death rates from ovarian cancer are predicted to fall by 2022 in EU countries

Death rates from ovarian cancer are predicted to fall by 2022 in EU countries

Independent drug action responsible for greater clinical efficacy of combination cancer therapies

Independent drug action responsible for greater clinical efficacy of combination cancer therapies

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

Anticancer drug may reduce mortality and speed up recovery for severe COVID-19 patients

Anticancer drug may reduce mortality and speed up recovery for severe COVID-19 patients

New combination treatment for recurrent ovarian cancer shows positive outcomes

New combination treatment for recurrent ovarian cancer shows positive outcomes

Age can affect response to adjuvant treatment among patients with resected melanoma

Age can affect response to adjuvant treatment among patients with resected melanoma

Common medication used to treat diabetic macular edema is less effective in Black patients

Common medication used to treat diabetic macular edema is less effective in Black patients

SARS-CoV-2 spike protein may induce analgesia

SARS-CoV-2 spike protein may induce analgesia

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

COVID-19 clinical trials show positive early results, says GlobalData

COVID-19 clinical trials show positive early results, says GlobalData

New treatment improves survival for people with common liver cancer

New treatment improves survival for people with common liver cancer

A faster and easier treatment option to prevent blindness in preterm infants

A faster and easier treatment option to prevent blindness in preterm infants

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

Maintenance chemotherapy after initial treatment more beneficial for metastatic colorectal cancer patients

Maintenance chemotherapy after initial treatment more beneficial for metastatic colorectal cancer patients